Insurance benefits for Pfizer’s heart drug Vyndamax uncertain

9 September 2021 - Pfizer’s Vyndamax (tafamidis), a treatment for transthyretin amyloid cardiomyopathy, got in the European Society of Cardiology’s ...

Read more →

Reimbursement uncertain for Piqray targeting PIK3CA mutation in breast cancer

7 September 2021 - The first and only targeted therapy to treat hormone receptor positive and human epidermal growth factor ...

Read more →

Acute myeloid leukaemia drug Xospata nears getting insurance benefits

3 September 2021 - Astellas Korea’s Xospata 40mg (gilteritinib fumarate), a treatment for acute myeloid leukaemia, has taken a step ...

Read more →

Pfizer’s acromegaly treatment receives reimbursement

2 September 2021 - Pfizer Korea said Thursday that the Ministry of Health and Welfare would begin to reimburse Somavert, ...

Read more →

CAR-T therapy Kymriah fails to get insurance benefits

2 September 2021 - The first CAR-T therapy, Kymriah (ingredient: tisagenlecleucel), failed to pass the review of a panel at ...

Read more →

Cancer treatments account for 9.3% of total drug claims in 2020

1 September 2021 - The National Health Insurance Service (NHIS) said that the reimbursement claims for anticancer drugs last year ...

Read more →

Roche to withdraw 2 Parkinson’s drugs from Korean market

27 August 2021 - Roche said it would withdraw Parkinson’s syndrome treatment Madopar 125 mg and 250 mg tablets from ...

Read more →

Government eases criteria for haemophilia A drug reimbursement

26 August 2021 - The Government said it would ease the immune tolerance induction treatment criteria for haemophilia A drug ...

Read more →

Avastin biosimilar may bring insurance benefits for Tecentriq

25 August 2021 - The government has been delaying discussing whether to allow reimbursement for Tecentriq (atezolizumab) due to concerns ...

Read more →

Talks to recover reimbursement for dementia treatment aid almost complete

18 August 2021 - The negotiations on retrieving the reimbursement of pharmaceutical pricing for choline alfoscerate drugs to help treat ...

Read more →

Will Government further expand reimbursement for rare leukaemia drugs?

17 August 2021 - As the Government has gradually increased reimbursement for combination drugs treating chronic lymphocytic leukaemia, patients’ hopes ...

Read more →

Companion diagnostics are growing rapidly worldwide. What about in Korea?

10 August 2021 - The global companion diagnostics market is expanding fast, but Korea has yet to develop related technologies, ...

Read more →

Novartis’ psoriatic arthritis drug to get expanded reimbursement

2 August 2021 - Novartis Korea said Monday its interleukin-17a inhibitor Cosentyx (secukinumab) began receiving reimbursement as a first-line biologics ...

Read more →

'New regulation limiting generic drugs will change industrial paradigm'

27 July 2021 - The Korea Pharmaceutical and Bio-pharma Manufacturers Association said the revision of the Pharmaceutical Affairs Act to ...

Read more →

‘MSD Korea proposed unprecedented offer for Keytruda reimbursement’

12 July 2021 - MSD’s Keytruda (pembrolizumab), immunotherapy for lung cancer, is the company’s flagship item that sold $14.38 billion ...

Read more →